PMID- 36032384
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2434-0790 (Electronic)
IS  - 2434-0790 (Linking)
VI  - 4
IP  - 8
DP  - 2022 Aug 10
TI  - Impact of Modified H(2)FPEF Score on Chronic Limb-Threatening Ischemia in 
      Patients With Lower Extremity Artery Disease Who Underwent Endovascular Therapy.
PG  - 378-387
LID - 10.1253/circrep.CR-22-0063 [doi]
AB  - Background: Lower extremity artery disease (LEAD) is an arterial occlusive 
      disease characterized by an insufficient blood supply to the lower limb arteries. 
      The H(2)FPEF score, comprising Heavy, Hypertensive, atrial Fibrillation, 
      Pulmonary hypertension, Elder, and Filling pressure, has been developed to 
      identify patients at high risk of heart failure (HF) with preserved ejection 
      fraction. This study assessed the impact of modified H(2)FPEF scores on chronic 
      limb-threatening ischemia (CLTI) in patients with LEAD. Methods and Results: This 
      study was a prospective observational study. Because the definition of obesity 
      differs by race, we calculated the modified H(2)FPEF score using a body mass 
      index >25 kg/m(2) to define obesity in 293 patients with LEAD who underwent first 
      endovascular therapy. The primary endpoints were newly developed and recurrent 
      CLTI. The secondary endpoint was a composite of events, including mortality and 
      rehospitalization due to worsening HF and/or CLTI. The modified H(2)FPEF score 
      increased significantly with advancing Fontaine classes. Multivariate Cox 
      proportional hazard analysis revealed that the modified H(2)FPEF score was an 
      independent predictor of newly developed and recurrent CLTI and composite events. 
      The net reclassification index and integrated discrimination improvement were 
      significantly improved by adding the modified H(2)FPEF score to the basic 
      predictors. Conclusions: The modified H(2)FPEF score was associated with LEAD 
      severity and future CLTI development, suggesting that it could be a feasible 
      marker for patients with LEAD.
CI  - Copyright (c) 2022, THE JAPANESE CIRCULATION SOCIETY.
FAU - Shikama, Taku
AU  - Shikama T
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
FAU - Otaki, Yoichiro
AU  - Otaki Y
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
FAU - Watanabe, Tetsu
AU  - Watanabe T
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
FAU - Takahashi, Hiroki
AU  - Takahashi H
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
FAU - Kurokawa, Tasuku
AU  - Kurokawa T
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
FAU - Tamura, Harutoshi
AU  - Tamura H
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
FAU - Kato, Shigehiko
AU  - Kato S
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
FAU - Nishiyama, Satoshi
AU  - Nishiyama S
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
FAU - Arimoto, Takanori
AU  - Arimoto T
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
FAU - Watanabe, Masafumi
AU  - Watanabe M
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine Yamagata Japan.
LA  - eng
PT  - Journal Article
DEP - 20220715
PL  - Japan
TA  - Circ Rep
JT  - Circulation reports
JID - 101746642
PMC - PMC9360988
OTO - NOTNLM
OT  - Chronic limb-threatening ischemia
OT  - H2FPEF score
OT  - Lower extremity artery disease
COIS- The authors have no conflicts of interest to declare.
EDAT- 2022/08/30 06:00
MHDA- 2022/08/30 06:01
PMCR- 2022/07/15
CRDT- 2022/08/29 04:40
PHST- 2022/06/24 00:00 [received]
PHST- 2022/06/24 00:00 [accepted]
PHST- 2022/08/29 04:40 [entrez]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/08/30 06:01 [medline]
PHST- 2022/07/15 00:00 [pmc-release]
AID - 10.1253/circrep.CR-22-0063 [doi]
PST - epublish
SO  - Circ Rep. 2022 Jul 15;4(8):378-387. doi: 10.1253/circrep.CR-22-0063. eCollection 
      2022 Aug 10.